Biodistribution of boron after intravenous 4-dihydroxyborylphenylalanine-fructose (BPA-F) infusion in meningioma and schwannoma patients A feasibility study for boron neutron capture therapy

Autor: Juha E. Jääskeläinen, Matti Seppälä, Martti Kulvik, Raine Hermans, Merja Rasilainen, Anders Paetau, Eija Järviluoma, Juha Laakso, Jyrki Vähätalo, Merja Kallio, Inkeri Ruokonen

Publikováno v: APPLIED RADIATION AND ISOTOPES. 106:207-212

We studied the uptake of boron after 100 mg/kg BPA infusion in three meningioma and five schwannoma patients as a pre-BNCT feasibility study. With average tumour-to-whole blood boron concentrations of 2.5, we discuss why BNCT could, and probably shou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::879af940fd7cd449e5bef34d7429edeb
http://juuli.fi/Record/0274709815

Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine

Autor: Markus Färkkilä, Martti Kulvik, Johanna Karila, Mikko Tenhunen, Iiro Auterinen, Sauli Savolainen, Juha Jääskeläinen, Juha Laakso, Inkeri Ruokonen, Mika Kortesniemi, Anders Paetau, Heikki Minn, Leena Kankaanranta, Merja Kallio, Petri Kotiluoto, Tom Serén, Päiivi Ryynänen, Eija Järviluoma, Antti Brander, Tiina Seppälä, Heikki Joensuu, Jyrki Vähätalo

Publikováno v: University of Helsinki

Two clinical trials are currently running at the Finnish dedicated boron neutron capture therapy (BNCT) facility. Between May 1999 and December 2001, 18 patients with supratentorial glioblastoma were treated with boronophenylalanine (BPA)-based BNCT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b6bd2f0e7d3b84ebe035e2d6a0bb68e
https://doi.org/10.1007/bf02699939

Handling anticancer drugs: from hazard identification to risk management?

Autor: Eija Järviluoma, Marja Sorsa, Mervi Hämeilä

Publikováno v: Annals of the New York Academy of Sciences. 1076

The potential health hazards involved with antineoplastic agents have been known for decades. Many anticancer drugs are recognized as carcinogens and genotoxins in experimental assays. Second cancers have been recorded in follow-up studies with treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c79641b3072ab6fc98d2230af8c8944
https://pubmed.ncbi.nlm.nih.gov/17119240

Clinical trials for glioma patients at the Finnish BNCT facility

Autor: Iiro Auterinen, Leena Kankaanranta, Sauli Savolainen, Tiina Seppälä, Markus Färkkilä, Merja Kallio, Martti Kulvik, Juha Laakso, Eija Järviluoma, Merja Rasilainen, Inkeri Ruokonen, Jyrki Vähätalo, Johanna Karila, Mika Kortesniemi, Petri Kotiluoto, Tom Serén, Mikko Tenhunen, Antti Brander, Anders Paetau, Salonen, O., Juha Jääskeläinen, Hanna Mäenpää, Heikki Joensuu

Publikováno v: VTT Technical Research Centre of Finland-PURE
Auterinen, I, Kankaanranta, L, Savolainen, S, Seppälä, T, Färkkilä, M, Kallio, M, Kulvik, M, Laakso, J, Järviluoma, E, Rasilainen, M, Ruokonen, I, Vähätalo, J, Karila, J, Kortesniemi, M, Kotiluoto, P, Serén, T, Tenhunen, M, Brander, A, Paetau, A, Salonen, O, Jääskeläinen, J, Mäenpää, H & Joensuu, H 2002, Clinical trials for glioma patients at the Finnish BNCT facility . in Proceedings of the XXXVI Annual Conference of the Finnish Physical Society ., 158, University of Joensuu, Joensuu, Selected papers. University of Joensuu, Department of Physics, no. 7, XXXVI Annual Conference of the Finnish Physical Society, Joensuu, Finland, 13/03/02 .

Boron neutron capture therapy (BNCT) is an experimental radiotherapy used in clinical trials in Europe, Japan and USA to treat malignant glioma and melanoma. In BNCT the highly lethal radiation (a, 7Li*) released in thermal neutron capture of boron-1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::7197cd4ccec7f7f8dfbb00b4525ad40e
https://cris.vtt.fi/en/publications/c4322f4b-7835-49da-ba75-a236abf13472